Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) have earned a consensus rating of “Moderate Buy” from the thirteen ratings firms that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, eleven have issued a buy rating and one has issued a strong buy rating on the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $117.30.

Several research analysts have commented on the company. HC Wainwright boosted their target price on Dianthus Therapeutics from $47.00 to $130.00 and gave the stock a “buy” rating in a research note on Monday, March 9th. Wells Fargo & Company initiated coverage on shares of Dianthus Therapeutics in a research note on Thursday. They issued an “overweight” rating and a $135.00 price target on the stock. Oppenheimer lifted their price target on shares of Dianthus Therapeutics to $145.00 and gave the company an “outperform” rating in a report on Monday, March 9th. Stifel Nicolaus set a $120.00 price objective on shares of Dianthus Therapeutics in a research report on Monday, March 9th. Finally, William Blair reissued an “outperform” rating on shares of Dianthus Therapeutics in a research note on Monday, March 16th.

Insider Transactions at Dianthus Therapeutics

In related news, CAO Edward Carr sold 43,682 shares of the business’s stock in a transaction on Thursday, March 12th. The stock was sold at an average price of $81.49, for a total transaction of $3,559,646.18. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Simrat Randhawa sold 33,830 shares of the business’s stock in a transaction on Thursday, March 12th. The stock was sold at an average price of $81.48, for a total value of $2,756,468.40. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 200,430 shares of company stock worth $16,332,702. Corporate insiders own 8.15% of the company’s stock.

Institutional Trading of Dianthus Therapeutics

A number of hedge funds have recently made changes to their positions in DNTH. Raymond James Financial Inc. bought a new stake in shares of Dianthus Therapeutics during the second quarter worth about $27,000. Parkside Financial Bank & Trust raised its holdings in Dianthus Therapeutics by 131.7% in the 3rd quarter. Parkside Financial Bank & Trust now owns 950 shares of the company’s stock valued at $37,000 after buying an additional 540 shares during the last quarter. Caitong International Asset Management Co. Ltd bought a new position in Dianthus Therapeutics in the 4th quarter valued at approximately $40,000. Russell Investments Group Ltd. acquired a new stake in Dianthus Therapeutics during the 3rd quarter worth approximately $64,000. Finally, Tower Research Capital LLC TRC boosted its position in Dianthus Therapeutics by 330.7% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,320 shares of the company’s stock worth $80,000 after buying an additional 3,317 shares during the period. 47.53% of the stock is owned by institutional investors and hedge funds.

Dianthus Therapeutics Stock Performance

Shares of DNTH stock opened at $77.76 on Friday. Dianthus Therapeutics has a fifty-two week low of $13.36 and a fifty-two week high of $88.02. The stock’s fifty day moving average price is $56.65 and its two-hundred day moving average price is $44.60. The company has a market cap of $3.46 billion, a PE ratio of -18.97 and a beta of 1.56.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its quarterly earnings results on Monday, March 9th. The company reported ($1.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.46). The business had revenue of $0.57 million for the quarter, compared to analyst estimates of $0.40 million. Dianthus Therapeutics had a negative return on equity of 38.85% and a negative net margin of 7,973.33%. On average, equities analysts predict that Dianthus Therapeutics will post -2.61 EPS for the current fiscal year.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.